This is in accordance with the previous study; TNF-α blockade with etanercept in T2DM patients had a significant beneficial effect on systemic inflammatory markers, but no improvement of metabolic insulin sensitivity was observed [40]. This evidence concerns the gene INS and type 2 diabetes mellitus.